Evidence map›Paper›PMID 24801707›Full record

ArticleJournal of molecular and cellular cardiology2014

Transcriptome from circulating cells suggests dysregulated pathways associated with long-term recurrent events following first-time myocardial infarction.

Rahul Suresh, Xing Li, Anca Chiriac, Kashish Goel, Andre Terzic, Carmen Perez-Terzic, Timothy J Nelson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular and cellular cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Genetics-Informed Mapping Identifies a CRIM1-Associated Endocardial Inflammatory Remodeling State in Acute Myocardial Infarction.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rahul SureshMayo Medical School, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA.
Xing LiDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA.
Anca ChiriacDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA.
Kashish GoelDivision of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA.
Andre TerzicDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA; Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA; Center for Regenerative Medicine, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA.
Carmen Perez-TerzicDivision of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA; Department of Physical Medicine and Rehabilitation, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA.
Timothy J NelsonDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA; Center for Regenerative Medicine, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA; Division of General Internal Medicine and Transplant Center, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester 55905 MN, USA. Electronic address: nelson.timothy@mayo.edu.
Mayo Clinic · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Mayo Clinic Center for Translational Science ActivitiesTL1TR000137 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$2.1M
NCATS NIH HHS TL1 TR000137NCATS NIH HHS UL1 TR000135
6 · The paper itself

Abstract

backgroundWhole-genome gene expression analysis has been successfully utilized to diagnose, prognosticate, and identify potential therapeutic targets for high-risk cardiovascular diseases. However, the feasibility of this approach to identify outcome-related genes and dysregulated pathways following first-time myocardial infarction (AMI) remains unknown and may offer a novel strategy to detect affected expressome networks that predict long-term outcome. METHODS AND

resultsWhole-genome expression microarray on blood samples from normal cardiac function controls (n=21) and first-time AMI patients (n=31) within 48-hours post-MI revealed expected differential gene expression profiles enriched for inflammation and immune-response pathways. To determine molecular signatures at the time of AMI associated with long-term outcomes, transcriptional profiles from sub-groups of AMI patients with (n=5) or without (n=22) any recurrent events over an 18-month follow-up were compared. This analysis identified 559 differentially-expressed genes. Bioinformatic analysis of this differential gene-set for associated pathways revealed 1) increasing disease severity in AMI patients is associated with a decreased expression of genes involved in the developmental epithelial-to-mesenchymal transition pathway, and 2) modulation of cholesterol transport genes that include ABCA1, CETP, APOA1, and LDLR is associated with clinical outcome.

conclusionDifferentially regulated genes and modulated pathways were identified that were associated with recurrent cardiovascular outcomes in first-time AMI patients. This cell-based approach for risk stratification in AMI could represent a novel, non-invasive platform to anticipate modifiable pathways and therapeutic targets to optimize long-term outcome for AMI patients and warrants further study to determine the role of metabolic remodeling and regenerative processes required for optimal outcomes.

Indexed as

TranscriptomeAdultAgedApolipoprotein A-IATP Binding Cassette Transporter 1Biological TransportCase-Control StudiesCholesterolCholesterol Ester Transfer ProteinsDisease ProgressionEpithelial-Mesenchymal TransitionFemaleFollow-Up StudiesGene Expression ProfilingGene Expression RegulationHumansABCA1 protein, humanAPOA1 protein, humanApolipoprotein A-IATP Binding Cassette Transporter 1CETP protein, humanCholesterolCholesterol Ester Transfer ProteinsLDLR protein, humanReceptors, LDLAcute myocardial infarctionbloodmicroarraypathway analysistranscriptome

Identifiers

PMID24801707
PMCPMC4115027
OpenAlexW1983855408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.